Member-only story
🌟 MindLight™: Pioneering the Future of Depression Care with 🧬 Biomarker Precision 🔬
Would you like to be featured in our newsletter🔥 and get noticed, QUICKLY 🚀? Simply send an email to editor@digitalhealthbuzz.com, and we can take it from there.
Introduction
Depression remains a leading cause of disability worldwide, affecting millions and presenting significant challenges in treatment. Traditionally, selecting the right antidepressant involves an educated guessing process, which can prolong patient suffering and delay effective care. Enter MindLightâ„¢, an innovative antidepressant response test developed by Circular Genomics. By leveraging cutting-edge circular RNA (circRNA) biomarkers, MindLight Antidepressant Response Testâ„¢ offers a predictive solution to streamline depression treatment and enhance patient outcomes.
The Challenge of Treating Depression
Major depressive disorder (MDD) impacts around 29% of U.S. adults, with SSRIs often…
